GP-Pharm announced last 8th May 2015, that its Lutrate Depot 22.5 mg has been approved through an EU decentralized procedure. Lutrate Depot 22.5 mg is a new trimestral Leuprolide depot formulation for the palliative treatment of advanced prostate cancer.
Lutrate is based on a by GP-Pharm developed patented technological platform of microspheres.
During its pivotal clinical trial phase III Lutrate Depot 22.5 mg achieved excellent castration levels in patients. Patients with prostate cancer will have the opportunity to benefit from the most effective sustained released formulation.
Lutrate Depot 22.5 mg is expected to become available in Europe during the fourth quarter of 2015.
Lutrate Depot 22.5 mg is the second Leuprolide depot formulation of GP Pharm after the successful registration of Lutrate Depot 3.75 mg in 2010 strengthens its urology and oncology portfolio.
Comentarios recientes